We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$7.74M
Cap. Flow
+$112M
Cap. Flow %
8.99%
Top 10 Hldgs %
54.36%
Holding
75
New
18
Increased
14
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$51.7M
2
RVMD icon
Revolution Medicines
RVMD
+$44.9M
3
MRUS
Merus
MRUS
+$41.2M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$31.8M
5
IRON icon
Disc Medicine
IRON
+$31.4M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$58.5M
2
DYN icon
Dyne Therapeutics
DYN
+$42.6M
3
IMVT icon
Immunovant
IMVT
+$34.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$32.1M
5
GERN icon
Geron
GERN
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 69.8%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$185M 14.91%
+2,000,000
New +$179M
SRPT icon
2
CALL
Sarepta Therapeutics
SRPT
$1.66B
$79M 6.35%
500,000
-700,000
-58% -$89.9M
APLS
3
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$76.7M 6.17%
+2,000,000
New +$90.6M
IDYA icon
4
IDEAYA Biosciences
IDYA
$3.41B
$59.7M 4.8%
1,700,000
+200,000
+13% +$7.92M
ARGX icon
5
argenx
ARGX
$57.4B
$58.1M 4.67%
+135,000
New +$51.7M
MRUS
6
DELISTED
Merus
MRUS
$50.3M 4.05%
+850,000
New +$41.2M
RVMD icon
7
Revolution Medicines
RVMD
$40.2B
$46.6M 3.75%
+1,200,000
New +$44.9M
GPCR icon
8
Structure Therapeutics
GPCR
$3.49B
$43.2M 3.47%
1,100,000
+379,942
+53% +$15.6M
IRON icon
9
Disc Medicine
IRON
$2.83B
$41.7M 3.35%
+925,000
New +$31.4M
OCUL icon
10
Ocular Therapeutix
OCUL
$1.86B
$35.2M 2.83%
5,150,000
-661,436
-11% -$4.08M
OLMA icon
11
Olema Pharmaceuticals
OLMA
$1.02B
$34.7M 2.79%
3,208,875
-1,175,000
-27% -$12.7M
VERA icon
12
Vera Therapeutics
VERA
$2.54B
$34.4M 2.76%
950,000
+375,000
+65% +$14.9M
MLTX icon
13
MoonLake Immunotherapeutics
MLTX
$1.59B
$33M 2.65%
+750,000
New +$31.8M
JANX icon
14
Janux Therapeutics
JANX
$935M
$31.4M 2.53%
750,000
+600,000
+400% +$28.2M
XNCR icon
15
Xencor
XNCR
$1.44B
$28.4M 2.28%
1,500,000
+850,000
+131% +$18.3M
SLN
16
Silence Therapeutics
SLN
$521M
$28M 2.26%
1,476,061
– –
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.66B
$23.7M 1.91%
150,000
-250,000
-63% -$32.1M
AKRO
18
DELISTED
Akero Therapeutics
AKRO
$18.8M 1.51%
800,000
– –
GPCR icon
19
CALL
Structure Therapeutics
GPCR
$3.49B
$17.7M 1.42%
450,000
– –
DSGN icon
20
Design Therapeutics
DSGN
$736M
$16.9M 1.36%
5,032,501
– –
ANNX icon
21
Annexon
ANNX
$855M
$16.2M 1.3%
3,300,000
+250,000
+8% +$1.29M
APLS
22
DELISTED
Apellis Pharmaceuticals
APLS
$15.3M 1.23%
400,000
-400,000
-50% -$18.1M
IMVT icon
23
Immunovant
IMVT
$8.09B
$15.2M 1.22%
575,000
-1,200,000
-68% -$34.1M
NUVL
24
DELISTED
Nuvalent
NUVL
$14.8M 1.19%
+195,000
New +$13.9M
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.32B
$14.6M 1.18%
+375,000
New +$15M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2024 Portfolio in Review

As of Q2 2024, Logos Global Management held 75 positions worth $1.24B, up 0.63% from $1.24B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Logos Global Management deployed $112M of net new capital in Q2 2024, opening 18 new positions and adding to 14 existing holdings. Its largest new stake was argenx: 135,000 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 77% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $42.6M trimmed.

  • Logos Global Management's largest Q2 2024 buy was argenx: 135,000 shares worth $58.1M.
  • Logos Global Management added most to Janux Therapeutics in Q2 2024, an estimated $28.2M increase.
  • Logos Global Management's biggest Q2 2024 reduction was Dyne Therapeutics, cutting an estimated $42.6M.
  • Logos Global Management fully exited Immunocore in Q2 2024, selling an estimated $58.5M.
  • Logos Global Management's ten largest holdings make up 54% of its $1.24B portfolio in Q2 2024.
  • Logos Global Management opened 18 new positions and closed 18 in Q2 2024.
  • Logos Global Management's portfolio value rose 0.63% quarter-over-quarter to $1.24B.

Based on Logos Global Management's 13F filing for Q2 2024, filed 14 Aug 2024.